Literature DB >> 22489288

NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.

Fiona Rinaldi, Elisabeth George, Amanda I Adler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22489288     DOI： 10.1016/s1470-2045(12)70044-x

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  Oncology trials--the elephant in the room.

Authors:  Rebecca Kirk; Lisa Hutchinson
Journal:  Nat Rev Clin Oncol       Date:  2012-03-28       Impact factor: 66.675

Review 2.  Targeted therapy in first line treatment of RAS wild type colorectal cancer.

Authors:  Vincenzo Formica; Mario Roselli
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

3.  Ephrin b2 receptor and microsatellite status in lymph node-positive colon cancer survival.

Authors:  Arik Drucker; Thomas Arnason; Sen Rong Yan; Mohammed Aljawad; Kara Thompson; Weei-Yuarn Huang
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

4.  Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.

Authors:  Michio Kimura; Eiseki Usami; Mina Iwai; Makiko Go; Hitomi Teramachi; Tomoaki Yoshimura
Journal:  Mol Clin Oncol       Date:  2016-09-15

5.  Trends in treatment and survival in older patients presenting with stage IV colorectal cancer.

Authors:  Gabriela M Vargas; Kristin M Sheffield; Abhishek D Parmar; Yimei Han; Aakash Gajjar; Kimberly M Brown; Taylor S Riall
Journal:  J Gastrointest Surg       Date:  2014-02       Impact factor: 3.452

6.  Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.

Authors:  Long Bai; Feng Wang; Zhe-Zhen Li; Chao Ren; Dong-Sheng Zhang; Qi Zhao; Yun-Xin Lu; De-Shen Wang; Huai-Qiang Ju; Miao-Zhen Qiu; Zhi-Qiang Wang; Feng-Hua Wang; Rui-Hua Xu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

7.  Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.

Authors:  Adriana Camargo Carvalho; Frederico Leal; Andre Deeke Sasse
Journal:  PLoS One       Date:  2017-04-12       Impact factor: 3.240

8.  Targeted therapies in colorectal cancer-an integrative view by PPPM.

Authors:  Suzanne Hagan; Maria C M Orr; Brendan Doyle
Journal:  EPMA J       Date:  2013-01-28       Impact factor: 6.543
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.